

# Immunotherapeutic mechanism on dendritic cell therapy for malignant glioma

メタデータ	言語: jpn 出版者: 公開日: 2021-10-22 キーワード (Ja): キーワード (En): 作成者: Tachibana, Osamu メールアドレス: 所属:
URL	<a href="https://doi.org/10.24517/00063691">https://doi.org/10.24517/00063691</a>

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 International License.



# 2003 Fiscal Year Final Research Report Summary

## Immunotherapeutic mechanism on dendritic cell therapy for malignant glioma

Research Project

### Project/Area Number

14571303

### Research Category

Grant-in-Aid for Scientific Research (C)

### Allocation Type

Single-year Grants

### Section

一般

### Research Field

Cerebral neurosurgery

### Research Institution

KANAZAWA UNIVERSITY

### Principal Investigator

**THCHIBANA Osamu** Kanazawa University, Kanazawa University Hospital, Lecturer, 医学部附属病院, 講師 (40211362)

### Project Period (FY)

2002 - 2003

### Keywords

malignant glioma / dendritic cell / immunotherapy / granzyme-B / death receptor / death effector

### Research Abstract

Intradermal cervical vaccinations of tumor-lysate or apoptotic GB cells-pulsed dendritic cells were administered to ten patients with malignant astrocytic tumors(9 : glioblastomas, 1 : anaplastic astrocytoma).Dendritic cell vaccination elicited systemic cytotoxicity in three of ten patients.A large number of intratumoral cytotoxic and helper T cell infiltration was detected in three of five patients who underwent reoperation or autopsy after vaccination. A large number of infiltrating T cells were immunoreactive for granzyme-B, and negative for Fas-ligand and TRAIL..Tumor volume was remarkably decreased in two cases after immunotherapy. Furthermore, more cytotoxic T cells were detected in cervical lymph nodes than in femoral lymph nodes of four autopsy cases. The median survival times for this study and control group were 499 and 410 days, respectively. These results suggested that immunoresponse for brain tumors depends on cervical Lymph nodes and infiltrating T cells attacked target cells using with granzyme-B.

# Research Products (6 results)

**All** Other  
**All** Publications

[Publications] Watanabe T, Hirota Y, Arakawa Y, Fujisawa H, Tachibana O, et al.: "Frequent LOH at chromosome 12q22-23 and Apaf-1 inactivation in glioblastoma."Brain Pathology. 13(4). 431-439 (2003) ▼

[Publications] Fujisawa H, Takabatake Y, Fukusato T, Tachibana O, et al.: "Molecular analysis of the rhabdoid predisposition syndrome in a child : a novel germline hSNF5/INI1 mutation and absence of c-myc amplification."J Neurooncol. 63(3). 257-262 (2003) ▼

[Publications] Fujisawa H, Marukawa K, Hasegawa M, Tohma Y, Hayashi Y, Uchiyama N, Tachibana O, et al.: "Genetic differences between neurocytoma and dysembryoplastic neuroepithelial tumor and oligodendroglial tumors."J Neurosurg.. 97(6). 1350-1355 (2002) ▼

[Publications] Watanabe T, Hirota Y, Arakawa Y, Fujisawa H, Tachibana O, et al.: "Frequent LOH at chromosome 12q22-23 and Apaf-1 inactivation in glioblastoma."Brain Pathol.Oct. 13(4). 431-439 (2003) ▼

[Publications] Fujisawa H, Takabatake Y, Fukusato T, Tachibana O, et al.: "Molecular analysis of the rhabdoid predisposition syndrome in a child : a novel germline hSNF5/INI1 mutation and absence of c-myc amplification."J Neurooncol.Jul. 63(3). 257-262 (2003) ▼

[Publications] Fujisawa H, Marukawa K, Hasegawa M, Tohma Y, Hayashi Y, Uchiyama N, Tachibana O, et al.: "Genetic differences between neurocytoma and dysembryoplastic neuroepithelial tumor and oligodendroglial tumors."J Neurosurg.Dec. 67(6). 1350-1355 (2002) ▼

**URL:**

Published: 2005-04-18